SS

Stephen Squinto

Chief Investment Officer

New York, New York

Investor
VC

Invests in

Stages:

Series A
Seed

  • Min Investment:

    $1,000,000.00

  • Max Investment:

    $75,000,000.00

  • Target Investment:

    $4,000,000.00

Skills

Life Sciences
Biotechnology
Lifesciences
Drug Development
Biopharmaceuticals
Oncology
Clinical Development
Technology Transfer
FDA
Pharmaceutical Industry
Drug Discovery
Clinical Trials
Medical Devices
Molecular Biology
Regulatory Affairs
Cancer
Management
Product Launch
Research
Biochemistry

Education

Lists including Stephen

AM
AR
AG
AH

Based in NYC

2600 people

AT
AS
AT
AH

All Series A Investors

14752 people

AM
AT
AS
AR

All Seed Investors

19695 people

Investments

Enlaza Therapeutics

Series A

Total Funding: $160M

iECURE

Series A

Total Funding: $120M

Gennao Bio

Series A

Total Funding: $40M

Chemomab

Post Ipo Equity

Total Funding: $76M

Gemini Therapeutics

Seed

Total Funding: $140M

Therachon

Series A

Total Funding: $100M

Arvinas

Series B

Total Funding: $140M

Audentes Therapeutics

Series A

Total Funding: $140M

Work Experience

JM
J.P. Morgan Asset Management

2022

  • Chief Investment Officer, JP Morgan Life Sciences Private Capital

    2022

GB
Gennao Bio

2021 - 2022

  • Executive Chairman

    2021 - 2022

O
OrbiMed

2015 - 2022

  • Executive Partner

    2019 - 2022

  • Venture Partner

    2015 - 2019

OrbiMed Advisors

2019 - 2022

  • Executive Partner

    2019 - 2022

AP
Alexion Pharmaceuticals, Inc.

1992 - 2015

  • Co-Founder; Exec VP, Head of R&D

    1992 - 2015

RP
Regeneron Pharmaceuticals, Inc.

1988 - 1992

  • Senior Leadership, Early Company Builder

    1988 - 1992